SynthesisFrontiers in medicine2026
Advances in rapid ADAMTS13 testing for thrombotic thrombocytopenic purpura: a systematic review of diagnostic assays and the role of clinical probability tools.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severe ADAMTS13 deficiency. This systematic review evaluates recent diagnostic advances, focusing on rapid assays, clinical prediction tools, and emerging biomarkers. Methods: Following PRISMA 2020 guidelines, we searched PubMed, Embase, Cochrane Library, Google Scholar, and ClinicalTrials.gov (2015-2026). We included studies evaluating ADAMTS13-based or adjunct biomarkers for TTP diagnosis, reporting diagnostic accuracy or turnaround time. Risk of bias was assessed using QUADAS-2. Results: From 2,217 records and 42 registry entries, 14 studies met inclusion criteria. ADAMTS13 activity <10% remained the key diagnostic threshold. Rapid automated platforms reduced turnaround time from >72 h to 17-35 min. Key findings include: HemosIL AcuStar assay (100% sensitivity, 94.6%-98.9% specificity, 33-min turnaround); CLEIA (17-min turnaround, near-perfect agreement with reference methods, Conclusion: TTP diagnosis is shifting from slow reference-laboratory confirmation toward an integrated strategy combining rapid automated ADAMTS13 testing, clinical probability scoring, and adjunct biomarkers. This approach enables earlier diagnosis, faster treatment initiation, and improved relapse surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.